JP2026511179A - 髄膜炎菌タンパク質に基づくワクチン製剤の製造方法 - Google Patents

髄膜炎菌タンパク質に基づくワクチン製剤の製造方法

Info

Publication number
JP2026511179A
JP2026511179A JP2025555730A JP2025555730A JP2026511179A JP 2026511179 A JP2026511179 A JP 2026511179A JP 2025555730 A JP2025555730 A JP 2025555730A JP 2025555730 A JP2025555730 A JP 2025555730A JP 2026511179 A JP2026511179 A JP 2026511179A
Authority
JP
Japan
Prior art keywords
fhbp
protein
range
modified
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025555730A
Other languages
English (en)
Japanese (ja)
Inventor
シャンカル ピサル，サンバージ
シャルマ アンナムラジュ，ダッタトレーヤ
マハラサカント デーレ，ラジーヴ
Original Assignee
セラム インスティチュート オブ インディア プライベイト リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラム インスティチュート オブ インディア プライベイト リミテッド filed Critical セラム インスティチュート オブ インディア プライベイト リミテッド
Publication of JP2026511179A publication Critical patent/JP2026511179A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2025555730A 2023-03-24 2024-03-22 髄膜炎菌タンパク質に基づくワクチン製剤の製造方法 Pending JP2026511179A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202321021121A IN202321021121A (https=) 2023-03-24 2023-03-24
IN202321021121 2023-03-24
PCT/IN2024/050300 WO2024201502A1 (en) 2023-03-24 2024-03-22 Meningococcal protein based vaccine formulations and methods for manufacturing thereof

Publications (1)

Publication Number Publication Date
JP2026511179A true JP2026511179A (ja) 2026-04-10

Family

ID=92903953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025555730A Pending JP2026511179A (ja) 2023-03-24 2024-03-22 髄膜炎菌タンパク質に基づくワクチン製剤の製造方法

Country Status (12)

Country Link
EP (1) EP4687967A1 (https=)
JP (1) JP2026511179A (https=)
KR (1) KR20250166279A (https=)
CN (1) CN121038809A (https=)
AR (1) AR132199A1 (https=)
AU (1) AU2024249503A1 (https=)
IL (1) IL323559A (https=)
IN (1) IN202321021121A (https=)
MX (1) MX2025011286A (https=)
TW (1) TW202444740A (https=)
UY (1) UY40678A (https=)
WO (1) WO2024201502A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025224732A1 (en) * 2024-04-26 2025-10-30 Techinvention Lifecare Private Limited Meningococcal hexavalent combination vaccine
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596240B (zh) * 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
EP2970920B1 (en) * 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110804102B (zh) * 2019-11-08 2021-07-20 苏州微超生物科技有限公司 B群脑膜炎球菌疫苗及其制备方法与应用

Also Published As

Publication number Publication date
AR132199A1 (es) 2025-06-04
MX2025011286A (es) 2025-11-03
CN121038809A (zh) 2025-11-28
KR20250166279A (ko) 2025-11-27
WO2024201502A1 (en) 2024-10-03
TW202444740A (zh) 2024-11-16
IN202321021121A (https=) 2024-04-19
IL323559A (en) 2025-11-01
AU2024249503A1 (en) 2025-10-16
EP4687967A1 (en) 2026-02-11
UY40678A (es) 2024-10-15

Similar Documents

Publication Publication Date Title
US11939357B2 (en) Modified meningococcal fHbp polypeptides
CA2865745C (en) Neisseria meningitidis compositions and methods thereof
JP2026511179A (ja) 髄膜炎菌タンパク質に基づくワクチン製剤の製造方法
CN112566657B (zh) 修饰的脑膜炎球菌fHbp多肽
JP6786394B2 (ja) 改変髄膜炎菌ｆＨｂｐポリペプチド
KR102626831B1 (ko) 수막구균 백신
CN110563818A (zh) 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
CN107823638B (zh) 一种b群脑膜炎球菌重组嵌合蛋白疫苗及其制备方法
RS56886B1 (sr) Antigeni pseudomonasa i kombinacije antigena
US20210369833A1 (en) Bacterial polysaccharide-conjugated carrier proteins and use thereof
OA22209A (en) Meningococcal protein based vaccine formulations and methods for manufacturing thereof.
JP2023544250A (ja) インフルエンザ菌ワクチン及びその使用方法
JP2025518168A (ja) 免疫原性組成物
HK1241890B (zh) 脑膜炎双球菌组合物及其方法